Investment Focus and Thesis

We focus on companies striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated. We seek innovative founders and companies targeting significant, unmet medical needs, with a focus on cell and gene therapy, oncology, oncology, neurosciences, rare diseases, and antimicrobial resistance.

Diverse Deal Network


Leverage Kineticos consulting advisors and academic partnerships

In-Depth Due Diligence


Tap into the Kineticos team for in-depth scientific, business, and industry knowledge

High-Impact Target Markets


Focus on cell and gene therapy, oncology, neurology, and rare diseases

Proven Company Creators


Combine people and processes to build new ventures


Contract Services and Enabling Technologies

Kineticos possesses a long history of operating, consulting, and investing in contract development and manufacturing organizations (CDMOs), equipment, and other enabling technologies.

Learn More
AdobeStock_142552910 (1)

Antimicrobial Resistance (AMR)

Kineticos invests in companies with disruptive technologies to bring their innovations to market and address other solutions for the growing burden of AMR.

Learn More

Biotech & Medtech

Kineticos partners and invests in both biotech and medtech companies striving to disrupt how drugs are developed and patients are treated across oncology, neurosciences, and rare diseases.

Learn More

Funding Coupled with Execution

Kineticos provides more than capital; we leverage our operator, scientific, and consultant expertise to help drive portfolio company strategy and growth. Our partnership approach delivers meaningful outcomes to patients, portfolio companies, and investors.

Kineticos seeks to partner and invest with companies at founding through their growth stage positioned to solve these service gaps and provide solutions to the advancing biologic sector.